Technology Transfer

Case Western Reserve University's Technology Transfer Office (TTO) serves our innovators with full-spectrum intellectual property services. For both faculty and students, we provide support for intellectual property and commercialization that spans the research & development continuum. We serve our researchers by assessing and building upon the commercial potential of new ideas and inventions.

Through interaction with our inventors, regional and national networks, including our affiliate healthcare systems, and potential commercial partners, we endeavor to determine the best path of translation and ultimate commercialization for University intellectual assets.

Consistent with the University's mission, the Technology Transfer Office is working towards enhancing its role in the promotion of an inclusive culture of global citizenship by exploring issues of access to essential medicines by resource-limited countries. This work includes moving towards the Universities Allied for Essential Medicine's Global Access Licensing Framework.

Recent News

A ‘game changer’ for people with sickle cell disease: Case Western Reserve University researcher, company, collaborating to develop blood test measuring the effects, potency of new gene therapies for sickle cell disease
--CWRU Daily, September 14, 2022

An inventive spirit, an impressive ranking
--CWRU Daily, September 8, 2022

Top faculty to be honored during CWRU’s inaugural Innovation Week
--CWRU Daily, September 8, 2022

Folio Photonics Announces Breakthrough Multi-Layer Optical Disc Storage Technology to Enable Industry-Disruptive Cost, Cybersecurity and Sustainability Benefits
--Folio Photonics, August 30, 2022

Please visit our TTO News webpage for more articles and press releases about TTO success stories.

For Questions About...

  • Your Invention Disclosure Form (IDF), please contact Joy Chen at 216.368.0362.
  • A Material Transfer Agreement (MTA) please contact Tyler Gray at 216.368.1401.
  • A Data Use Agreement (DUA), please contact
  • Anything else, please contact Daniel Pendergast at 216.368.0184.